A Clinical Trial in Mild to Moderate Alzheimer’s Disease — The ATH-1017-AD-0202 Study

Alzheimer's Clinical Trials Melbourne

Alzheimer’s disease is a neurodegenerative disorder that affects learning, memory, and other normal brain functions. Neurodegeneration is characterised as the progressive loss of structure or function of brain cells.

ATH-1017 is a new small molecule that has been shown in early research to enhance learning, memory and executive functions such as reasoning and planning. In addition, initial studies have found that ATH-1017 may work to promote increased growth and survival of brain cells which are usually damaged in Alzheimer’s disease.

This study medication has been developed as a subcutaneous (under the skin) daily injection.

To compare how well this drug works, participants will be randomly assigned to 3 different groups:

  • 80 mg ATH-1017;
  • 40mg ATH-1017;
  • and placebo (1:1:1).

Therefore, all participants have a 2 in 3 chance of receiving the ATH-1017 active study drug.

This study will require participation for up to 35 weeks including 10 onsite visits during that period. A 26-week open-label extension where participants receive the active drug may be available upon completion of the study.

Main Inclusion criteria*:

  • Age 55 to 85 years
  • Clinical diagnosis of mild to moderate Alzheimer’s disease dementia
  • Availability of a study partner who spends at least 4 to 6 hrs per day with participant, for at least 4 days a week
  • If receiving medication for symptomatic Alzheimer’s Disease, the participant should have been on a stable approved dose for at least 3 months prior to the screening visit

*Please note: there are additional criteria that must be met in order to qualify to participate in this study.

Interested?
Contact NeuroCentrix Research Team
Tell us how to contact you